National Institutes of Health: Plasmacytoma trials
The registry lists 11 Plasmacytoma studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 6Phase 2 5Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaTerminatedNCT03031730Phase 1Results posted
- Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT00984165Phase 2Results posted
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
- Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
- Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
- Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00033332Phase 3
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
- Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00019097Phase 2
- Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
- 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00003853Phase 2